Regen BioPharma Inc. Chairman Discusses the Rationale for Pursuing Autoimmune Indications by Activating the Nuclear Receptor NR2F6
18 months ago, Regen BioPharma Inc. (OTCQB: RGBP)(OTCQB: RGBPP) commenced a program to identify small molecules that inhibit the NR2F6 nuclear receptor. The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. Regen BioPharma believes that by inhibiting the NR2F6 nuclear receptor, […]
Regen BioPharma’s Chief Scientific Officer Explains the Link Between its NR2F6 Medicinal Chemistry and Three-Dimensional X-Ray Structure Programs
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) recently began a program to determine the three-dimensional structure of the NR2F6 nuclear receptor. In addition, the Company recently reported that its NR2F6 medicinal chemistry program identified key structural elements in small molecules that make them active and specific towards the NR2F6 target.
Regen BioPharma, Inc. Announces Former Eli Lilly Executive and Current CVS Board Member will Lead Newly Formed Business Advisory Board (BAB)
Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) announced that former Eli Lilly executive Jean-Pierre Millon will serve as chairman of its newly formed business advisory board (BAB). The Company also announced that two esteemed life science and healthcare executives have agreed to serve as members of the BAB. The advisory board will assist Regen’s […]
Regen BioPharma, Inc. Begins Program to Determine the 3- Dimensional Crystal Structure of NR2F6
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has begun a program to determine the 3-dimensional structure of NR2F6 both with and without the Company’s proprietary small molecule drugs bound to it. The Company recently reported that it has identified key structural elements in small molecules that make them active and specific towards the NR2F6 […]
Regen BioPharma, Inc. Researchers Capitalize on Key Structure in Compounds that Activate Checkpoint NR2F6 for the Potential Treatment of Autoimmune Diseases
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) believes it has taken full advantage of its recent prior discovery in developing small molecule drugs that activate NR2F6. The Company recently reported that it identified key structural elements in small molecules that make them active and specific towards the NR2F6 target. Now, further chemical testing has […]
Regen BioPharma, Inc. Researchers Demonstrate Direct Binding of Proprietary Agonists to Immune Checkpoint NR2F6
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) scientists have used a standard biochemical assay to determine if some of its small molecules that have been shown to activate NR2F6 in cells, physically interact with NR2F6 in vitro. The Company reports that the experiments indicate that some of Regen’s proprietary small molecules bind to, and […]
Regen BioPharma Issues End of Fiscal Year Shareholder Letter
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) President Dr. Harry Lander issued the following fiscal year end shareholder letter: As the end of Regen’s fiscal year 2017 approaches on September 30th, I would like to summarize our progress during the past twelve months and look to the future.
Regen BioPharma, Inc. Researchers Identify Key Structure in Compounds that Activate NR2F6
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), in conjunction with its medicinal chemistry partner, ChemDiv, Inc., believes it has made a fundamental discovery in developing small molecule drugs that activate NR2F6. The Company reports that recently identified novel chemical compounds that activate NR2F6 have key structural elements that make them active and specific.
August 10, 2017 | SOURCE: PR NEWSWIRE
Regen BioPharma, Inc. Addresses Potential Impact of Recent Bristol Myers Squibb’s $2.3 Billion Acquisition of IFM Therapeutics. Small molecule biotech companies fetching trophy values from large Pharma
August 9, 2017 | SOURCE: PR NEWSWIRE
Regen BioPharma, Inc. Addresses Potential Impact of Recent Bristol Myers Squibb $2.3 Billion Acquisition of IFM Therapeutics. Small molecule biotech companies fetching trophy values from large Pharma